BrainTale Biomarker Platform Supports Drug Development in Demyelinating Disease
11 July 2024 - 11:15PM
Business Wire
- First peer-review publication in Brain
unveiling the relevance of BrainTale’s biomarker platform to
monitor disease evolution and demonstrate therapeutic efficacy for
cerebral adrenoleukodystrophy (CALD) patients - BrainTale
imaging-derived biomarkers provide insights into white matter
microstructure alterations while being strongly correlated to total
lesion load and neurofilaments light chain (NfL) - BrainTale
technology platform allows rapid and automated production of robust
non-invasive biomarkers in any imaging facility
BrainTale, a medtech deciphering white matter to enable better
brain care, spin-off of the Paris Region Greater Hospitals
announces the publication of the article by Marianne Golse in the
peer-reviewed journal Brain entitled “Leriglitazone halts disease
progression in adult patients with early cerebral
adrenoleukodystrophy“ supporting the benefits of its biomarker
platform as non-invasive reliable and objective lesion-assessment
tool in the drug development targeting white matter diseases. It
enables the non-invasive monitoring of disease evolution and
demonstration of therapeutic efficacy in adrenoleukodystrophy
patients.
Long underestimated in neuroscience, white matter, which
represents 60% to 80% of the human brain, plays a key role in its
proper functioning, development, and aging, whether normal or
pathological. Accordingly, since its creation in 2018, BrainTale
has been developing non-invasive, accessible, actionable in
multicentric frameworks, and clinically validated measurement and
predictive tools for patients suffering from brain diseases, such
as CALD. With a strong collaborative approach, the company’s
ambition is to provide investigators with relevant measure of the
brain to improve patient care and clinical development of new
disease-modifying drugs.
CALD is an X-linked demyelinating disease that progresses
rapidly and usually leads to death within a few years. As a rare
condition, underdiagnosed and insufficiently understood, CALD is an
example of crucial medical need patient population awaiting
therapeutic options and reliable diagnostic and monitoring
tools.
The article “Leriglitazone halts disease progression in adult
patients with early cerebral adrenoleukodystrophy” published in
Brain and accessible here shows notably that DTI biomarkers as
provided by Braintale are relevant markers of myelin integrity in
humans, and that they are sensitive to disease progression in
myeloneuropathy and CALD patients population.
Connecting white matter quantification with clinical symptoms,
the data provided by the BrainTale platform demonstrated strong
correlation with total lesion load and neurofilament light chains
(NfL). Of note, BrainTale reports allow easy interpretation of
calibrated DTI metrics, offering to imaging centers and physicians
the white matter measures and biomarker perspective in their daily
practice.
Professor Fanny Mochel, Coordinator of the Paris Rare disease
center for leukodystrophies and final author of the publication,
comments: "BrainTale supports patient care through optimization of
new disease-modifying drug development alongside its routine use in
clinical settings. With its “DTI 2.0” technology approach, the
BrainTale platform can monitor disease evolution and contribute to
assessing therapeutic efficacy – a needed game-changer for
leukodystrophy patients".
About BrainTale BrainTale is an innovative European
medtech company measuring the brain through white matter
quantification and standardization based on a commercially
available software medical device solution. This regulatory-cleared
AI software offers quality controlled, non-invasive, reliable and
clinically validated reports after diffusion tensor MRI data
processing. BrainTale enables drug developers, leading academic
researchers and physicians to improve patient care by understanding
neuroinflammatory and neurodegenerative conditions, assess brain
lesions evolutions and take appropriate decisions in the clinic and
during drug development. BrainTale empowers the scientific and
medical community with objective measure to transform brain
care.
Because brain diseases have become the medical issue of our
time, we can no longer wait. At BrainTale, we strongly believe that
by exploring better, we can treat faster, together.
For more information, please visit www.braintale.eu
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711726945/en/
BrainTale – Lisa Marcheval, communication manager,
lisa.marcheval@braintale.eu Press relations: Anna Casal,
casal.anna@gmail.com, +33650615571